Abstract Interferon-b (IFN-b) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-b have been hampered by secondary toxicity and the short half-life of IFN-b in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-b to tumors. In this study, we tested the efficacy of AAVmediated local delivery of IFN-b for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-b delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-b consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-b resulted in efficient retinal infection and sustained IFN-b production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-b had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-b may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.
Introduction
Retinoblastoma is a cancer of the developing retina that begins in utero and is usually diagnosed in the first few years of life. After neuroblastoma and leukemia, retinoblastoma is the third most common form of cancer in infants with an incidence of 1/20,000 live births in the United States (Ries et al. 1999) . Children with unilateral retinoblastoma typically undergo surgical enucleation, which results in a 95% cure rate in developed countries. However, about 40% of children with retinoblastoma are born with a germ-line mutation of the RB1 gene and develop multiple bilateral retinoblastomas at an earlier age (Naumova and Sapienza 1994) . The current approach to treatment of these patients includes systemic chemotherapy, to reduce tumor burden, followed by a combination of focal therapies that include laser therapy and cryotherapy. Even with this intensive treatment, the eyes of approximately 40% of children with advanced bilateral retinoblastoma are still lost (Rodriguez-Galindo et al. 2003) . Poor intravitreal penetration of anti-cancer drugs is one of the limitations of current therapies. To overcome this hurdle many researchers and clinicians are now focusing on novel methods to deliver anti-tumorigenic compounds to the eyes of children with retinoblastoma by subconjunctival injection (Murray et al. 1997; Hayden et al. 2000; Van Quill et al. 2005) or direct injection of chemotherapeutic agents into the vitreous (T. Yanagisawa, personal communication). The advantage of these approaches is that they can lead to much higher intravitreal levels of chemotherapeutic drugs while avoiding many of the side effects associated with systemic broad-spectrum chemotherapy.
Another strategy to specifically target retinoblastoma cells in the eye is gene therapy. Using an innovative suicide gene-therapy approach, Hurwitz et al. injected an adenoviral vector (AdV-TK) that expresses the herpes simplex virus thymidine kinase (HSV-TK) gene into established tumors. Cells expressing HSV-TK are sensitive to subsequent exposure to ganciclovir. Following a preclinical study using this strategy in animal models (Hurwitz et al. 1999) , the investigators tested the safety of this approach in children with refractory tumor seeding in the vitreous. Vector was injected via a transcorneal approach adjacent to vitreal seeds. Therapy was well tolerated and seven out of eight patients showed a clinical response, demonstrating that this strategy is feasible and potentially effective (Chevez-Barrios et al. 2005) .
Adeno-associated virus (AAV) is a nonpathogenic human parvovirus, which is dependent on a helper virus, usually adenovirus or herpesvirus, to propagate. AAV virions are small nonenveloped particles with a 4.7-kb linear single-stranded DNA genome and are capable of infecting both dividing and quiescent cells. AAV infection involves a multistep process starting with cell surface binding, followed by viral uptake, intracellular trafficking, nuclear localization, uncoating, and second-strand DNA synthesis (Li et al. 2005) , this latter process being the ratelimiting step to successful target cell transduction.
AAV has a number of desirable characteristics for gene therapy including a lack of pathogenicity, minimal immunogenicity, and the ability to transduce postmitotic cells in a stable and efficient manner (Dinculescu et al. 2005) . The retina is a sheltered environment in which AAV vectors are able to maintain high levels of transgene expression in the retinal pigmented epithelium (RPE), photoreceptors, or ganglion cells for long periods of time after a single treatment (Dinculescu et al. 2005 ) with little, if any, viral spread to other tissues outside of the eye. Subretinal injection of AAV vectors leads to RPE and photoreceptor transduction (Ali et al. 1996 (Ali et al. , 1998 Bennett et al. 1999; Rolling 2004 ) while intravitreal injection leads to efficient ganglion cell transduction (Dudus et al. 1999; Guy et al. 1999; Liang et al. 2001; Folliot et al. 2003) . AAV-mediated gene delivery is currently being tested in a variety of animal models of retinal disease including recessive Leber congenital amaurosis (LCA), both dominant and recessive retinitis pigmentosa (RP), X-linked reinoschisis (RS), and retinal neovascular disease (Campochiaro 2002; Dejneka et al. 2003; Surace and Auricchio 2003; Dinculescu et al. 2005) .
In this study, the efficacy of AAV-mediated delivery of interferon-b (IFN-b) for the treatment of retinoblastoma in preclinical models was evaluated. Interferon-b is a pleiotropic cytokine that targets a variety of intracellular signaling pathways (Der et al. 1998; Fish et al. 1999) . First identified for their potent antiviral activities in the 1950s, type I interferons (a/b) have become recognized for their anti-tumor activities in both animal models as well as in clinical studies against solid and hematologic malignancies (Einhorn and Strander 1993; Pfeffer et al. 1998; Kirkwood 2002; Sondak 2002; Dranoff 2004) . Documented activity as an anticancer compound as single therapy or as a combined modality with other treatments has been shown in a variety of hematologic diseases including hairy cell leukemia, chronic myeloid leukemia (CML), myeloma, and B and T cell lymphomas (Gibson 2002; Ludwig 2004; Rohatiner et al. 2005; Voutsadakis 2000) . A number of solid tumors have also been found to be responsive to IFN, including melanoma, renal cell carcinoma, and midgut carcinoids (Kirkwood and Tarhini 2003; Coppin et al. 2005) .
Despite the potent anti-neoplastic activity of IFN-b, clinical trials using IFN-b to treat human cancer patients have been disappointing (Einhorn and Grander 1996) . This is due in part to the pharmacology of systemic IFN-b administration. Side effects limit the maximum dose that can be administered, and the short half-life limits the duration of IFN-b exposure in the tumor. To overcome these limitations of IFN-b treatment of cancer, a genetherapy approach has been shown to result in local target cell transduction and continuous IFN-b production at the site of the tumor (Choi et al. 2004; Hendren et al. 2004; Lu et al. 1999; Qin et al. 1998; Yoshida et al. 2004) .
Retinoblastoma is an ideal cancer for this type of treatment approach because an intravitreal injection of a viral vector encoding IFN-b may lead to long-term local exposure of IFN-b to the growing tumor in the retina, subretinal space, choroids, and vitreous. In this study, we tested the efficacy of AAV-mediated delivery of IFN-b using preclinical models of retinoblastoma. We found that a potent anti-tumor effect can be achieved using this strategy with minimal systemic exposure of IFN-b or spread of the AAV viral vector outside of the eye. AAVmediated delivery of IFN-b may serve to complement the existing conventional approaches for treating this debilitating childhood cancer.
Materials and Methods
Cell Culture Y79 and Weri1 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in culture in RPMI with 10% FCS (McFall et al. 1977) . SEM cells were generously provided by Dr. Wing Leung (St. Jude Children's Research Hospital, Memphis, TN). Y79 cells were engineered to stably express luciferase using a method previously described (Dickson et al. 2007 ).
Immunolabeling, Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End Labeling (TUNEL), Caspase, and Bromodeoxyuridine Assays Bromodeoxyuridine (BrdU), Caspase, and TUNEL assays were carried out as described previously Cepko 2000, 2001; Zhu et al. 2002) . Detailed protocols are available at http://www.stjude.org/dyer.
Fluorescent-activated Cell Sorting
DNA content was analyzed by fluorescent-activated cell sorting. Cells were washed with PBS and resuspended in a solution containing 0.05 mg/ml propidium iodide, 0.1% sodium citrate, and 0.1% Triton X-100. Samples were then treated with RNase, filtered through a 40-lm nylon mesh, and analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ).
Viable Cell Calculation Following Drug Treatment
Following drug treatment, the total number of cells (N) from hemacytometer cell counting were scored followed by Guava Viacount Ò and Guava Nexin TM assays (Guava technologies, Haywood, CA) to determine the proportion of cells that were metabolically active (M) and the proportion of cells that had initiated apoptosis (T). All of these data were combined to obtain the number of viable cells (C v ) in the following equation:
The proportion of viable cells is the ratio of the number of viable cells (C v treated) in the treated sample divided by the number of viable cells (C v untreated) in the untreated sample. All of the cell culture experiments were carried out twice, in triplicate to generate the data shown in Fig. 1 .
Animals/Tissue
Wild-type Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). All animal procedures were approved by the institutional ACUC and complied with NIH guidelines.
Microscopy
Bright-field and single-cell fluorescent images were obtained using a Zeiss Axioplan 2 fluorescent microscope with the Zeiss AxioCam digital camera.
Bioluminescence Imaging of Y79-LUC Cells In Vivo
Orthotopic retinoblastoma xenografts were established in wild-type rats by intravitreal injection of 1 9 10 3 Y79-LUC cells using 33 gauge syringe (Hamilton, Reno, NV) at P0. AAV-IFN-b was injected using 33 gauge syringe at P7. To monitor luciferase activity, rats were anesthetized with 2% inhaled isofluorane followed by an i.p. injection of luciferin (Xenogen, INC., Alameda, CA) according to the manufacturer's instructions. Five minutes later, animals were imaged using the Xenogen IVIS 200 bioluminescence imaging system. Animals were monitored for health and humanely sacrificed prior to rupture of eye due to rapid growth of tumor.
rAAV Vector Construction, Production, and Purification
The cDNAs for human interferon-beta (hIFN-b) and human placental alkaline phosphatase (PLAP) were purchased from InvivoGen (San Diego, CA). AAV vector plasmids based on the ITRs of AAV serotype 2 and containing these cDNAs were then constructed. Each included the CMV-IE enhancer, b-actin promoter, a chicken b-actin/ rabbit b-globin composite intron, and a rabbit b-globin polyadenylation signal. Functional AAV vectors in which the AAV-2 vector genome was encapsidated with capsid proteins of AAV serotype 1, 2, 5, or 8 were then generated by the methods described previously (Davidoff et al. 2005) . Standard slot-blot analysis was used to determine the vector particle titer. The vector stocks were consistently free of contamination with wild-type AAV and cellular and adenoviral proteins. Intravitreal injections consisted of 1 9 10 9 vector particles in 1 ll PBS.
Human Interferon-b Immunoassay
Levels of human IFN-b in mouse vitreous and plasma were determined using a commercially available immunoassay (ELISA) (Biosource International, Camarillo, CA). The standard used in the human IFN-b ELISA kit is calibrated against the NIH reference for human IFN-b. The reported level of sensitivity for hIFN-b is 100 pg/ml in this kit.
Determination of Vector Biodistribution
To evaluate the biodistribution of AAV8 CAG hIFN-b vectors, 1 lg of genomic DNA extracted from the retina and liver was subjected to PCR using primers which amplified a 434-bp region (5 0 primer: 5 0 -CTGTTGTGCTT CTCCACTACAG-3 0 and 3 0 primer: 5 0 -GCCTTCAGGTA ATGCAGAATCC-3 0 ), as described previously (Nathwani et al. 2001 ).
Detection of Anti-AAV8 Antibodies
Serum samples from rats were screened for the presence of antibodies against AAV8 by determining the ability of the serum to inhibit transduction of 293T cells by an AAV8 vector encoding GFP, as previously described (Nathwani et al. 2001) . The neutralizing antibody titer was arbitrarily calculated as reciprocal of the highest dilution, which inhibited transduction of 293T cells by 50%.
Results

Retinoblastoma Cell Lines are Sensitive to Interferon-b in Culture
A variety of tumor cell types have been found to be sensitive to IFN-b. In order to test the sensitivity of retinoblastoma cells to IFN-b, we performed a series of experiments on cultured retinoblastoma cell lines. As a positive control, we used SEM leukemia cells which have been shown to be sensitive to a variety of cytokines (Greil et al. 1994) . Cultured cells were exposed to human recombinant IFN-b (Avonex Ò ) at concentrations ranging from 500 to 10,000 IU/ml for 72 h. At the end of the culture period, the cell number, proportion of viable cells, and proportion of apoptotic cells were scored in triplicate for each IFN-b concentration.
The SEM cells showed a maximum reduction in viability at 500 IU/ml (Fig. 1a) . Cell cycle analysis demonstrated that there is a G0/G1 arrest in SEM cells exposed to IFN (Fig. 1b) and this was consistent with data from BrdU-labeling studies (Fig. 1c, d ). There does not appear to be any increase in apoptosis in SEM cells exposed to IFN-b as measured by FACS with 7-AAD or Annexin-V staining (Fig. 1e) . These data are consistent with previously published data showing that SEM cells undergo cell cycle exit in response to IFN-b exposure (Greil et al. 1994) .
Weri1 retinoblastoma cells (McFall et al. 1977 ) also showed a maximum reduction viability at 500 IU/ml IFN-b (Fig. 1f) . However, in contrast to the SEM cells, there is no significant cell cycle arrest in IFN-b-treated Weri1 cells as measured by FACS or BrdU labeling (Fig. 1g-i) . Immunostaining for activated Caspase 3 and TUNEL showed a significant increase in apoptosis of Weri1 cells exposed to IFN-b (Fig. 1j, k) suggesting that this was the predominant mechanism for the reduction in cell viability.
Maximum reduction in viability of Y79 retinoblastoma cells (Chevez-Barrios et al. 2000) occurred at 2,500 IU/ml of IFN-b (Fig. 1l ). There was a small increase in cells in the G1 phase of the cell cycle following exposure to IFN-b (Fig. 1m) , and this is consistent with the decrease in the proportion of BrdU-labeled cells following IFN-b treatment (Fig. 1n) . Little, if any, increase in cell death was observed in Y79 cells exposed to IFN-b (Fig. 1o) .
Quantitation of Retinoblastoma Growth in Orthotopic Xenografts
We have previously published the development of an orthotopic retinoblastoma xenograft model using Y79 cells that constitutively express the luciferase reporter gene (Y79-Luc) (Laurie et al. 2005 ). However, we have not directly analyzed the efficiency of luciferase quantitation per cell in this xenograft model. In order to characterize the Y79 cell line itself, we plated 10 3 , 10 4 , 10 5 , and 10 6 cells in triplicate in a 96-well dish. We added the luciferase substrate (luciferin) and imaged using the Xenogen IVIS 200 (Fig. 2a) . As expected, there was a linear relationship between cell number and photons/s/cm 2 (Fig. 2b) . Importantly, the photons/cm 2 s per cell was very similar over this broad range of cell density (Fig. 2c) .
To measure the efficiency of luciferase detection in vivo, we injected 10,000, 25,000 and 50,000 Y79-Luc cells into the vitreous of P14 rat pups (Fig. 2d) . Prior to injection, the cells were mixed with luciferin to quantitate the photons/s/cm 2 per eye in vivo. The photons/s/cm 2 increased as expected with increasing cell number (Fig. 2e ) and the number of photons/s/cm 2 per cell (Fig. 2f ) was very similar to that seen for cultured cells (compare Fig. 2f to c). These data suggest that there is little, if any, reduction in the efficiency of luciferase detection when the cells are inside the eye compared to a tissue culture dish.
Next, we tested the efficiency of luciferin transport across the blood-retinal barrier. Newborn rat pups received an intraocular injection of 1,000 Y79-Luc cells and 14 days later the luciferase activity was measured using the Xenogen IVIS 200 system (Fig. 2g) . We then removed the tumor from each eye, dissociated the cells, and scored the proportion of viable cells. The photons/s/cm 2 increased with increasing cell number in each eye providing a strong correlation between luciferase activity and tumor burden (Fig. 2h) . However, the overall efficiency of detection (photons/s/cm 2 per cell) was approximately 10-fold lower than the cultured cells or direct injection of luciferin (Fig. 2c, f) due to the restricted penetration of luciferin across the blood-retinal barrier (Fig. 2i) .
AAV-mediated Delivery of IFN-b to the Vitreous
As a first step, we tested AAV vectors encoding luciferase with serotypes 1, 2, 5, and 8 to determine which was the most efficient in transducing the neonatal rat eye. Bioluminescent imaging revealed that vectors pseudotyped with AAV8 capsid generated the highest mean signal (data not shown). Therefore, all the subsequent studies were performed with AAV8 vectors.
Next, we injected an AAV vector encoding alkaline phosphatase (Fig. 3a) into the vitreous of P14 rats to determine which cell types were infected in the retina. We found that the photoreceptors were the predominant cell type infected (Fig. 3b, c) . When we performed a similar experiment with P14 tumor bearing rats, we observed a similar pattern of retinal infection as well as infection of the Y79 tumor cells themselves (Fig. 3d) .
In order to determine how much IFN-b is produced in the eye following intravitreal injection of AAV-IFN-b virus, we injected the virus at P14 and then monitored the levels of IFN-b in the vitreous and plasma at three timepoints (3, 10, and 42 days after injection). Three days following vector injection, intravitreal levels of IFN-b were 20 ng/ml and remained stable for 6 weeks (Fig. 3e) . The plasma levels of IFN-b were 7 ng/ml 3 days following vector injection, 2 ng/ml by day 10, and undetectable at 42 days (Fig. 3e) . To determine whether the vector had spread outside of the eye, we performed PCR analysis of DNA extracted from the retina and liver (the site of the greatest tropism for systemic AAV8 (Davidoff et al. 2005) to detect the viral genome. We found no detectable vector genome in the liver (Fig. 3f ). We also measured the level of systemic anti-AAV8 antibodies after intravitreal injection of AAV8 CAG hIFN-b and found the development of a low level titer (Fig. 3g) , suggesting that there had been some systemic exposure to the vector upon intravitreal administration.
Response of Orthotopic Retinoblastoma Xenografts to Local AAV-IFN-b
To determine whether AAV-IFN-b could mediate an antitumor effect in vivo, we mixed either AAV-IFN-b or AAV-AP with Y79-Luc retinoblastoma cells and injected 1,000 cells into the eyes of newborn rat pups. We monitored the luciferase expression from P14 to P26 and found that of AAV-IFN-b led to a significant (P \ 0.01 for days 24, 25 and 26) reduction in luciferase expression during this time period (Fig. 4a, b) . Next, we established tumors by injecting Y79-Luc cells into the eyes of newborn rat pups and at P14, injected AAV-IFN-b or AAV-AP virus into the vitreous. The dose of AAV-IFN-b (or AAV-AP) was 2 9 10 9 vector particles per eye. In the control eyes (AAV-AP), there was an increase in luciferase expression over time until the animals had to be euthanized for humane reasons due to tumor burden (Fig. 4c, d ). In the eyes injected with AAV-IFN-b, there was little, if any, increase in tumor burden over this time period (Fig. 4c, d ). In total, 18 treated eyes and 9 control eyes were assayed. 2 correlate directly with cell number (b) and photons/s/cm 2 per cell were constant over all of the different cell densities tested (c). Then, 10,000, 25,000, and 50,000 Y79-Luc cells were mixed with luciferin and injected into the vitreous of P14 rat pups and subsequently imaged (d). The photons/s/cm 2 increased as expected with increasing cell number (e) and the photons/s/cm 2 per cell was similar to that seen in culture (f). Next, Y79-Luc cells were injected to the vitreous of P14 rats, and luciferin was administered by i.p. injection to measure the efficiency of luciferin transport across the blood-retinal barrier (g). There was a correlation between the number of cells and the photons/s/cm 2 (h) but the photons/s/cm 2 per cell was approximately 10-fold lower due to the transport of luciferin across the blood-retinal barrier (i)
Discussion
Previous studies have established the feasibility of gene therapy to treat retinoblastoma in preclinical models and Phase I clinical trials (Chevez-Barrios et al. 2005 ). Here we extended those studies and tested the efficacy of AAVmediated delivery of IFN-b for the treatment of retinoblastoma. We found that Weri1 retinoblastoma cells undergo apoptosis in the presence of IFN-b while Y79 retinoblastoma cells undergo cell cycle arrest in the presence of IFN-b. In vivo, AAV vectors efficiently infected the retina and retinoblastoma xenografts and continued to produce IFN-b during the first 6 weeks. There was no detectable spread of the virus outside of the eye and plasma levels dropped off to undetectable levels by 6 weeks of age. Treatment of established orthotopic retinoblastoma xenografts with local administration of AAV-IFN-b resulted in a cessation of tumor expansion consistent with the results from IFN-b treatment in culture.
The difference between this study and those previously published data on gene therapy for the treatment of retinoblastoma are threefold. First, we delivered a cytokine (IFN-b) that directly affects tumor survival and growth. The previous studies delivered the HSV-TK gene that sensitized the tumor cells to systemic delivery of ganciclovir. Second, in this study, infection of the tumor cells, the retina, or other ocular tissues is sufficient to deliver IFN-b to the vitreous and reduce tumor burden. In the previous study, only the infected tumor cells were sensitized to ganciclovir. Third, we used an AAV vector delivery method and the previous study delivered HSV-TK using adenovirus. One advantage of AAV is that it is being widely used for gene-therapy-based approaches to treat a variety of retinopathies. This delivery method is well To provide additional evidence for minimal AAV spread outside of the eye following an intravitreal injection, a transduction inhibition assay was performed to measure anti-AAV8 antibody titer in naive rats, those that received an intravitreal injection and rats that received an intravenous injection of AAV8 (g) characterized, and there have been no reports of retinal toxicity associated with long-term viral infection. This study is the first report of retinoblastoma sensitivity to cytokines and also the first report of AAV-mediated gene therapy for retinoblastoma. Based on these studies, we propose that AAV-IFN-b may complement existing approaches for the treatment of retinoblastoma. We do not anticipate that it would be used as monotherapy but may be combined with local delivery of chemotherapy by subconjunctival injection as well as focal therapies such as laser and cryotherapy.
It is also important to note that we used the cell line (Y79-Luc, see Fig. 1 ) that was the least sensitive to IFN-b in our xenograft cell experiments. We felt this was appropriate because gene therapy to treat retinoblastoma would provide the greatest potential benefit for patients with tumors that were refractory to other treatments, and Y79 cells are the most aggressive available cell line that we have available.
Cytokines such as IFN-b are useful in cancer therapy because they can directly affect tumor cell viability and growth. In addition, cytokines can modulate the immune response to tumors providing a complementary anti-tumor mechanism of action. Unfortunately, systemic administration of recombinant cytokines can lead to toxicity and side effects, which include flu-like symptoms, fever, chills, muscle aches, weakness, diarrhea, and depression (Wadhwa et al. 2002) . Short half-life of cytokines such as IFN-b pose an additional challenge for their application as anticancer agents (Hendren et al. 2004 ). We addressed both of these challenges by delivering IFN-b to the eye with an AAV vector. We found that AAV-mediated delivery of IFN-b led to vitreal levels of IFN-b sufficient to mediate an anti-tumor effect even using our least sensitive cell line (Y79 cells). In addition, there was not significant spread of the virus to other organs such as the liver and the plasma levels dropped to undetectable levels by 6 weeks of age even though the levels in the vitreous were maintained.
It is interesting to note that there was IFN-b in the plasma a few days after the injection of the virus but these levels tapered off by 6 weeks of age. It is possible that the retinal vasculature was transiently compromised as a result of the injection. It is also possible that intraocular pressure was changed transiently as a result of the injection and this led to higher IFN-b penetration into the circulation. The highest levels detected in the plasma were not sufficient to mediate the side effects typically associated with IFN-b so we believe this transient systemic exposure would not lead to significant side effects in humans. In this study, we did not address this directly because we used human IFN-b against human retinoblastoma cells in a rodent host. The rodent IFN-b receptor does not bind the human IFN-b so any side effects that may result from systemic exposure to IFN-b were masked in this study. In addition, any immunomodulatory effects were also masked because our experiments only addressed direct cytotoxicity of IFN-b against retinoblastoma cells. Therefore, it is possible that the combination of direct cytotoxicity and immunomodulatory effects may lead to an even greater reduction in tumor burden following infection with AAV-IFN-b.
This study sets the framework for a series of future studies in preclinical models prior to Phase I clinical trials. Future studies will focus on elucidating these immunomodulatory effects of IFN-b by using rodent IFN-b in a rodent host. These experiments will also address the systemic toxicity associated with the low levels of IFN-b in the plasma shortly after the viral injection. Long-term toxicity in the retina and surrounding ocular tissues must also be addressed prior to clinical trials. Finally, the best combination of chemotherapy to complement the AAV-IFN-b gene therapy should be analyzed along with the best method of drug delivery (systemic versus subconjunctival).
